Peptides Are Insane
A biochemist-turned-fitness-creator runs the three categories of peptides through the evidence — and finds one category proven, one promising but thin, and one basically wishful thinking.
Yank’s 5 0:50 of a 19:07 video
Yank’s 5
5 lines and 4 Yank summary points across 19:07AI summary
Generated by Yank from this source. A summary, not quoted language.
He consults a board-certified physician throughout and fact-checks claims against available research to assess which peptides are genuinely supported by evidence.
A 2018 trial of 2,000 people showed that semaglutide produced 34 lbs of average weight loss versus 6 lbs with a placebo.
Yank summary
What matters, in Yank’s words, each linked to where the source says it.
One in every eight US adults reports using fat loss peptides, and tens of millions are taking them globally.
In a 2018 trial, semaglutide users lost an average of 34 lbs versus 6 lbs in the placebo group over 16 months.
Without weightlifting and proper protein intake, about 40% of weight lost on GLP-1 peptides is lean mass.
BPC-157 has only ever been formally studied in 30 people across three small pilot studies with no placebo or control group.
Yank’s 5
Yank’s 5 are Yank’s picks from this source. Want something else?
BPC-157, the Wolverine peptide all over the internet, has only ever been formally studied in 30 people.
The negligible human-trial sample exposes the gap between BPC-157's internet fame and its actual scientific evidence base.
In context
variety of different tissues, including muscles, tendons, and ligaments. Once again, it accelerated healing everywhere it went. But there's a catch, and it's a big one. All those studies were done on rats, rabbits, and [music] dogs, not humans. BPC157, the Wolverine peptide all over the internet, has only ever been formally studied in 30 people. That's it. Compared with semaglutide or tzepide which have been tested on tens of thousands of people across multi-year phase 3 placeboc controlled clinical trials. BPC57 has just three pilot studies with barely a small handful of
Receipt
Without weightlifting and proper protein intake, about 40% of the weight lost on a GLP-1 peptide is lean mass.
Muscle loss becomes a near-inevitable consequence when GLP-1 users skip resistance training and adequate protein, framing exercise as non-optional.
In context
started taking a peptide instead of exercising, which sucks if true, because exercise has mental health benefits that you simply can't replace. And you will lose a lot of muscle if you take one of these peptides without lifting. In fact, without weightlifting and proper protein intake, about 40% of the weight lost on the GLP1 peptide is lean mass. That's almost certainly not due to the peptide itself, but simply the fact that people are just losing a lot of weight without eating enough protein or training hard enough. I do think a lot of people using
Without weightlifting and proper protein intake, about 40% of the weight lost on the a GLP-1 peptide is lean mass.
Receipt
Obesity has biological drivers that we can't just necessarily out-discipline or out-willpower — the peptide hits receptors in the brain to eliminate those same biological drivers. Kind of evens the playing field.
A doctor reframes GLP-1 use not as laziness but as correcting a biological disadvantage, directly countering the "shortcut" stigma.
In context
eating a dashlike diet and do exercise for hypertension. Nobody shames anybody for taking an anti-hypertensive or tells them it's a shortcut. Obesity has biological drivers in it that we can't just necessarily outdisipline or out willpower and so it goes and hits the receptors in the brain to basically not have those same biological drivers anymore. Kind of evens the playing field. So I don't see it like a shortcut at all. >> Yeah. I think people almost like hate on shortcuts a little bit too much too, right? Like to me there's a fine line between like taking a shortcut and just
Obesity has biological drivers in it that we can't just necessarily outdisipline out-discipline or out willpower and so it goes and hits out-willpower — the peptide hits receptors in the brain to basically not have eliminate those same biological drivers. anymore. Kind of evens the playing field.
Receipt
Virtually all compounds marketed as anti-aging solutions follow the same pattern: they probably work in rats, might work in pigs, sometimes work in other primates, and then do basically nothing in humans.
A consistent cross-species failure pattern warns that promising animal data on anti-aging compounds routinely collapses before it reaches humans.
In context
of okay, though, because humans are already uniquely well adapted for longevity. When you compare humans to other mammals of a similar size, you consistently see that humans live much longer. And virtually all the compounds out there that are being marketed as anti-aging solutions follow a similar pattern. They probably work in rats. They might work in pigs. Sometimes they'll work in other primates. And then they do basically nothing when it comes to humans. But we don't really need to look for a peptide to help us live longer anyway because the science is already quite
humans live much longer. And Virtually all the compounds out there that are being marketed as anti-aging solutions follow a similar the same pattern: they probably work in rats, They might work in pigs, sometimes they'll work in other primates, and then they do basically nothing in humans.
Receipt
Retatrutide — just through phase 3 clinical trials — caused 28% weight loss; starting at 250 lbs, you'd be expected to lose around 71 pounds in about a year and a half.
A concrete real-world weight example anchors retatrutide's 28% figure, showing why newer multi-receptor peptides are rapidly eclipsing semaglutide.
In context
single peptide. But that was 2018. These days, there are newer peptides that honestly kind of wipe the floor with ompic. For example, compared to semiglutides 15% weight loss, a newer peptide called trazepatide caused 23% weight loss in a similar time frame. And redatride just passed through phase 3 clinical trials caused 28% weight loss. That means if you started at 250 lbs and took retatride for about a year and a half, you'd be expected to lose around 71 pounds. The reason they work so well is that semiglutide only activates one receptor, GLP1, but tzepide activates two
Retatrutide — just through phase 3 clinical trials — caused 28% weight loss; That means if you started starting at 250 lbs, and took retatride for about a year and a half, you'd be expected to lose around 71 pounds in about a year and a half.
Receipt
Didn’t see the line you wanted? Choose your own
Make something from it
Ask this source
Ask about anything in this video. Yank answers only from what the source says, shows you where, and tells you when the source doesn’t say.
Answers are written by Yank from the source, for you. Nothing you ask is saved or published.